CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...

Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia. The FDA has granted approval to bosutinib (Bosulif) for the treatment of ...

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...

Please provide your email address to receive an email when new articles are posted on . The indication applies to use of the agent by pediatric patients aged 1 year or older with chronic phase ...

The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...

Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Europe Chronic Myeloid Leukemia Market and Competitive Landscape Highlights - 2016" report to their offering. The ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Chronic Myeloid Leukemia Epidemiology and Patient Flow Analysis - 2017" report to their offering. The results of ...